Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FBR054
MIFTS: 44

Fibroma

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Fibroma

About this section

MalaCards integrated aliases for Fibroma:

Name: Fibroma 12 74 29 54 15 17

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050871
Sources

Summaries for Fibroma

About this section
Disease Ontology : 12 A connective tissue benign neoplasm composed of fibrous or connective tissues that derives from mesenchymal tissue.

MalaCards based summary : Fibroma is related to chondromyxoid fibroma and ossifying fibroma. An important gene associated with Fibroma is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Innate Immune System and Striated Muscle Contraction. The drugs Sorafenib and Protein Kinase Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include bone, ovary and skin, and related phenotypes are cardiovascular system and cellular

Wikipedia : 74 Fibromas are benign tumors that are composed of fibrous or connective tissue. They can grow in all... more...

Sources

Related Diseases for Fibroma

About this section

Diseases related to Fibroma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 708)
# Related Disease Score Top Affiliating Genes
1 chondromyxoid fibroma 32.7 VIM S100A1 DES ACTC1
2 ossifying fibroma 32.5 USP6 SERPINA3 NF1 CDC73
3 skin tag 32.1 SERPINA3 PTCH1 CD34
4 testicular fibroma 32.1 CD34 CALB2
5 liver fibroma 32.0 VIM CD34 CALB2
6 rare tumor 31.4 DES ACTC1
7 fibromatosis 31.3 VIM DES CTNNB1 ACTC1
8 basal cell nevus syndrome 31.2 PTCH1 NF1 CTNNB1
9 cutaneous fibrous histiocytoma 31.1 VIM SERPINA3 S100A1 F13A1 DES CD68
10 fibrosarcoma 30.9 VIM MALAT1 DES ACTC1
11 exophthalmos 30.8 NF1 CD68 CD34
12 pleomorphic lipoma 30.8 SERPINA3 CD68 CD34
13 epulis 30.7 VIM SERPINA3 DES CD68
14 chondroma 30.7 S100A1 NF1 CTNNB1 ACTC1
15 myoma 30.7 MUC16 CD34 ACTC1
16 infantile digital fibromatosis 30.6 VIM DES
17 spindle cell sarcoma 30.6 VIM SERPINA3 DES CD34 ACTC1
18 fasciitis 30.6 VIM USP6 CD34 ACTC1
19 chordoma 30.6 VIM SERPINA3 S100A1 DES
20 perineurioma 30.5 VIM S100A1 ACTC1
21 ameloblastoma 30.5 SERPINA3 PTCH1 CTNNB1 CALB2
22 leiomyoma 30.5 VIM S100A1 PTCH1 DES CD34 ACTC1
23 odontogenic myxoma 30.4 VIM SERPINA3
24 lipomatosis, multiple 30.4 SERPINA3 PECAM1 NF1 DES CD34
25 perivascular epithelioid cell tumor 30.4 VIM DES ACTC1
26 basal cell carcinoma 30.3 PTCH1 IVL CTNNB1 CD68 CD34
27 giant cell reparative granuloma 30.3 USP6 SERPINA3 NF1 CD68
28 ovarian fibrothecoma 30.3 DES CALB2 ACTC1
29 neurofibroma 30.2 VIM S100A1 NF1 F13A1 CD34 ACTC1
30 cystadenoma 30.2 SERPINA3 MUC16 CALB2
31 congenital epulis 30.2 VIM SERPINA3 DES CD68
32 neuroma 30.2 SERPINA3 NF1 CD68 CD34
33 pericardial effusion 30.1 MUC16 CD68 CD34
34 benign mesothelioma 30.1 VIM PECAM1 CD34 CALB2
35 mesenchymal cell neoplasm 30.1 SERPINA3 PECAM1 CD68 CD34
36 dermatofibrosarcoma protuberans 30.1 VIM SERPINA3 S100A1 F13A1 DES CD34
37 benign giant cell tumor 30.1 VIM SERPINA3 DES ACTC1
38 myofibroma 30.0 SERPINA3 S100A1 F13A1 DES CD34
39 pseudo-meigs syndrome 30.0 MUC16 CALB2
40 spindle cell lipoma 30.0 VIM S100A9 DES CD34 ACTC1
41 myoblastoma 30.0 CD68 CALB2
42 angiomyoma 30.0 PECAM1 CD34
43 erythema elevatum diutinum 30.0 S100A9 PECAM1 F13A1 CD34
44 chondroid chordoma 30.0 VIM SERPINA3 S100A1
45 tenosynovial giant cell tumor 30.0 USP6 SERPINA3 CD68 CD34
46 adenoid cystic carcinoma 30.0 VIM SERPINA3 S100A1 CTNNB1
47 verruciform xanthoma of skin 29.9 SERPINA3 CD68
48 heart fibrosarcoma 29.9 PECAM1 CD34
49 ovarian angiosarcoma 29.9 PECAM1 CD34
50 parathyroid adenoma 29.9 TSC1 CTNNB1 CDC73

Graphical network of the top 20 diseases related to Fibroma:



Diseases related to Fibroma
Sources

Symptoms & Phenotypes for Fibroma

About this section

MGI Mouse Phenotypes related to Fibroma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 ACTC1 CDC73 CTNNB1 DES F13A1 NF1
2 cellular MP:0005384 10.03 ACTC1 CD34 CDC73 CTNNB1 DES NF1
3 homeostasis/metabolism MP:0005376 10 ACTC1 CD34 CDC73 CTNNB1 DES F13A1
4 muscle MP:0005369 9.65 ACTC1 CDC73 CTNNB1 DES NF1 PECAM1
5 respiratory system MP:0005388 9.28 CDC73 CTNNB1 F13A1 NF1 PECAM1 PTCH1
Sources

Drugs & Therapeutics for Fibroma

About this section

Drugs for Fibroma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
2 Protein Kinase Inhibitors Phase 3
3
Toremifene Approved, Investigational Phase 2 89778-26-7 3005573
4
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
5
Denosumab Approved Phase 2 615258-40-7
6
nivolumab Approved Phase 2 946414-94-4
7
Ipilimumab Approved Phase 2 477202-00-9
8
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
9
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
10
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
11
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
12
Imidazole Experimental, Investigational Phase 2 288-32-4 795
13 Vaccines Phase 2
14 Estrogen Receptor Modulators Phase 2
15 Antineoplastic Agents, Hormonal Phase 2
16 Imatinib Mesylate Phase 2 220127-57-1 123596
17
Liposomal doxorubicin Phase 2 31703
18 Antineoplastic Agents, Immunological Phase 2
19 Immunoglobulins Phase 2
20 Antibodies, Monoclonal Phase 2
21 Antibodies Phase 2
22 Chlorpheniramine, phenylpropanolamine drug combination Phase 2
23 Anti-Infective Agents Phase 1, Phase 2
24 Antifungal Agents Phase 1, Phase 2
25 Immunosuppressive Agents Phase 1, Phase 2
26 Antibiotics, Antitubercular Phase 1, Phase 2
27 Immunologic Factors Phase 1, Phase 2
28 Anti-Bacterial Agents Phase 1, Phase 2
29
Triamcinolone Approved, Vet_approved Phase 1 124-94-7 31307
30 Hormone Antagonists Phase 1
31 Hormones Phase 1
32 Anti-Inflammatory Agents Phase 1
33 Triamcinolone hexacetonide Phase 1
34 glucocorticoids Phase 1
35 triamcinolone acetonide Phase 1
36 Triamcinolone diacetate Phase 1
37
Povidone-iodine Approved 25655-41-8
38
Iodine Approved, Investigational 7553-56-2 807
39
Ethanol Approved 64-17-5 702
40
silver nitrate Approved, Investigational 7761-88-8
41
Povidone Approved 9003-39-8 131751496
42
Chlorhexidine Approved, Vet_approved 55-56-1 9552079 2713
43
Estradiol Approved, Investigational, Vet_approved Early Phase 1 50-28-2 5757
44
Polyestradiol phosphate Approved Early Phase 1 28014-46-2
45
Cadexomer iodine Experimental 94820-09-4
46 Anesthetics
47 Anti-Infective Agents, Local
48 Chlorhexidine gluconate
49 Cola
50 Estrogens Early Phase 1

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
2 Single Blinded Randomized Study of Volume Reduction of Uterine Fibroids After Uterine Artery Embolization Versus Computer Tomography or Ultrasound Guided Percutaneous Microwave Ablation Evaluated by Magnetic Resonance Imaging Unknown status NCT02942537 Phase 2, Phase 3
3 A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF) Active, not recruiting NCT02066181 Phase 3 Sorafenib Tosylate
4 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF) Active, not recruiting NCT03785964 Phase 3 Nirogacestat oral tablet;Placebo Oral Tablet
5 Open Label Phase II Clinical Trial of Myoma Immunotherapy Unknown status NCT03550703 Phase 2
6 Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets Unknown status NCT02353429 Phase 2 Toremifene
7 A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids Completed NCT02323646 Phase 2 Placebo;Telapristone Acetate
8 Phase II Study to Evaluate Glivec (Imatinib Mesylate) to Induce Progression Arrest in Aggressive Fibromatosis / Desmoid Tumors Not Amenable to Surgical Resection With R0 Intent or Accompanied by Unacceptable Function Loss Completed NCT01137916 Phase 2 Imatinib
9 Multicentric Phase I/II Study Evaluating the Efficacy and Toxicity of Imatinib in Adult Patients With Aggressive Fibromatosis That Cannot be Treated by Surgery or Curative Radiotherapy Completed NCT00287846 Phase 1, Phase 2 imatinib mesylate
10 Phase II Pilot Study Of Moderate Dose Radiotherapy For Inoperable Aggressive Fibromatoses Completed NCT00030680 Phase 2
11 A Phase II Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis) Completed NCT02495519 Phase 2 Imatinib
12 Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label Recruiting NCT03363763 Phase 2 Sirolimus 0.2%;Sirolimus 0.4%;Placebo ointment
13 Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis Recruiting NCT03966742 Phase 2
14 An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Rich Tumors of Bone Recruiting NCT03605199 Phase 2 Denosumab
15 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
16 A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014) in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors Recruiting NCT04195399 Phase 2 Nirogacestat
17 Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis Active, not recruiting NCT01981551 Phase 2 PF-03084014
18 A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Active, not recruiting NCT01265030 Phase 1, Phase 2 Sirolimus
19 Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors in Adults and Children (CHP-914) Withdrawn NCT00978146 Phase 2 Hydroxyurea
20 A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors Active, not recruiting NCT03627741 Phase 1 Triamcinolone Acetonide
21 3-dimensional Versus Conventional Laparoscopy in Patients Undergoing Total Hysterectomy for Benign Disease - A Randomised Clinical Trial Unknown status NCT02610985
22 Operative Hysteroscopy for Fibroma by Classic Resection Versus Morcellation: a Ramdomised Study Unknown status NCT02406898
23 Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients Unknown status NCT02547831
24 A Comparison of Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy. Unknown status NCT01289314
25 Peripheral Primitive Fibromatosis. Study Evaluating a Simple Initial Monitoring With Search of Scalability Predictive Factors and Registration of Treatments in Case of Progression Unknown status NCT01801176
26 Clinicopathological and Molecular Correlation of Acrochordon in Relation to Human Papillomavirus Infection Unknown status NCT00520078
27 Randomized Clinical Trial on Traditional Healing Versus Moist Healing Environment (MHE) Applied to Minor Surgery in the Exeresis of Skin Tags Completed NCT04161274
28 Biomarkers for Tuberous Sclerosis Complex: An International Multicenter Observational Longitudinal Protocol Recruiting NCT02654340
29 The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Recruiting NCT02402244
30 The Evaluation of Health-related Quality of Life Issues Experienced by Patients With Desmoid-type Fibromatosis Recruiting NCT04289077
31 A Prospective Analysis of Active Observation in Patients With Desmoid-Type Fibromatosis Recruiting NCT04281381
32 National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis Active, not recruiting NCT02867033
33 Biomarker for Hyaline Fibromatosis Syndrome - An International, Multicenter, Epidemiological Protocol Active, not recruiting NCT03196115
34 A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol Active, not recruiting NCT00919269
35 South Miami Hospital Fibroid Registry Terminated NCT02362009
36 Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation Terminated NCT01998854
37 Pilot Investigation of 18F-FES PET/CT Imaging of Desmoid Tumors Terminated NCT02374931 Early Phase 1 F-18 16 Alpha-Fluoroestradiol

Search NIH Clinical Center for Fibroma

Sources

Genetic Tests for Fibroma

About this section

Genetic tests related to Fibroma:

# Genetic test Affiliating Genes
1 Fibroma 29
Sources

Anatomical Context for Fibroma

About this section

MalaCards organs/tissues related to Fibroma:

40
Bone, Ovary, Skin, Heart, Breast, Uterus, Kidney
Sources

Publications for Fibroma

About this section

Articles related to Fibroma:

(show top 50) (show all 7119)
# Title Authors PMID Year
1
Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. 54 61
19033865 2009
2
Loss of the PTCH1 gene locus in cardiac fibroma. 61 54
18329553 2008
3
Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. 54 61
18292222 2008
4
Is loss of heterozygosity at 9q22.3 (PTCH gene) and 19p13.3 (STK11 gene) involved in the pathogenesis of ovarian stromal tumors? 54 61
16084949 2005
5
Role of the hedgehog/patched signaling pathway in oncogenesis: a new polymorphism in the PTCH gene in ovarian fibroma. 54 61
15659790 2004
6
Origin of stellate giant cells in oral fibrous lesions determined by immunohistochemical expression of vimentin, HHF-35, CD68 and factor XIIIa. 61 54
15370129 2004
7
Solitary sclerotic fibroma of skin: a possible link with pleomorphic fibroma with immunophenotypic expression for O13 (CD99) and CD34. 61 54
14744088 2003
8
Ultrastructural and immunohistochemical characterization of the so-called giant multinucleate cells in cutaneous collagenomas. 61 54
12147091 2002
9
Fibroma and inflammatory myofibroblastic tumor of the heart. 61 54
11745071 2001
10
S100A6 expression in fibrohistiocytic lesions. 54 61
11401666 2001
11
Two cases of supernumerary ovary: one with large fibroma with Meig's syndrome and the other with endometriosis and cystic change. 61 54
11795834 2001
12
Cytokeratin expression in trichoblastic fibroma (small nodular type trichoblastoma), trichoepithelioma and basal cell carcinoma. 54 61
10215762 1999
13
Benign fibromatous tumors of the testis and paratesticular region: a report of 9 cases with a proposed classification of fibromatous tumors and tumor-like lesions. 61 54
9060599 1997
14
Pleomorphic hamartoma of the subcutis: a lesion with possible myogenous and neural lineages. 61 54
7593822 1995
15
An immunohistochemical study of odontogenic mixed tumours. 54 61
7543314 1995
16
Phenotypic characterisation of stellate and giant cells in giant cell fibroma by immunocytochemistry. 61 54
7523665 1994
17
So-called "immature dentinoma": a case presentation and histological comparison with ameloblastic fibrodentinoma. 61 54
8164161 1994
18
Histologic and immunohistochemical evidence for considering ovarian myxoma as a variant of the thecoma-fibroma group of ovarian stromal tumors. 54 61
7688213 1993
19
Mesothelial and related neoplasms in children and adolescents: a clinicopathologic and immunohistochemical analysis of eight cases. 61 54
1384016 1992
20
Cytoskeletal gene expression in normal and neoplastic human odontogenic epithelia. 61 54
1721670 1991
21
Immunohistochemical analysis for desmin in normal and neoplastic ovarian stromal tissue. 61 54
2159271 1990
22
Fibroma-like perivascular epithelioid cell tumor: a rare case in a long bone. 61
32944815 2021
23
Ubiquitin-specific Peptidase 6 (USP6)-associated Fibroblastic/Myofibroblastic Tumors: Evolving Concepts. 61
33608306 2021
24
Subperiosteal chondromyxoid fibroma: a rare case involving the humeral diaphysis. 61
32803376 2021
25
Discovery of an endometrioid cancer lymph node metastasis without primary tumor in a context of Lynch syndrome. 61
33421625 2021
26
Active decompression and distraction sugosteogenesis for the treatment of calcifying odontogenic cyst. 61
32676749 2021
27
[Pulmonary lymphangioleiomyomatosis (LAM)]. 61
33420570 2021
28
Benign skull and subdural lesions in patients with prior medulloblastoma therapy. 61
32876801 2021
29
Ameloblastic Fibroma in Mandibular Anterior Tooth Region: A Case Report. 61
33583881 2021
30
Cemento-ossifying fibroma and juvenile ossifying fibroma: Clarity in terminology. 61
33129707 2021
31
Risk Factors for Left Ventricular Dysfunction Following Surgical Management of Cardiac Fibroma. 61
33517672 2021
32
Endonasal Endoscopic Approach for a Psammomatous Juvenile Active Ossifying Fibroma: 2-Dimensional Operative Video. 61
33588435 2021
33
Alternative method for the diagnosis of acid cases of unknown cause: Transvaginal natural orifice transluminal endoscopic surgery. 61
33197989 2021
34
Desmoplastic fibroma of the jaw bones: A series of twenty-two cases. 61
33204607 2021
35
Clinical laboratory features of Meigs' syndrome: a retrospective study from 2009 to 2018. 61
32651935 2021
36
MRI evaluation of solid soft tissue masses of the fingers with pathology correlation. 61
33341071 2021
37
Fibro-Osseous Lesions Of The Craniofacial Complex In Horses: 30 Cases (2001-2019). 61
33399249 2021
38
Laparoscopic single-stapler technique in rectosigmoid resection in women with deep infiltrating endometriosis. 61
33413952 2021
39
Adipocyte-rich CTNNB1-mutated Intramuscular Gardner Fibroma Progressing to Desmoid Fibromatosis. 61
33104413 2021
40
Fine-Needle Aspiration Cytology in Preoperative Diagnosis of Bone Lesions: A Three-Year Study in a Tertiary Care Hospital. 61
33181515 2021
41
Conservative parenchymal surgery in testicular tumors. 61
33507639 2021
42
Ventricular tachycardia as the presenting feature in two patients with cardiac lipoma and cardiac fibroma. 61
33068721 2021
43
Surgical Management of Arteriovenous Malformation in the Foot: A Case Study. 61
33129675 2021
44
Surgical resection of a giant peripheral ossifying fibroma in mouth floor managed with fiberscopic intubation. 61
33489156 2021
45
Fibroma of the tendon sheath of the neck. 61
32307266 2021
46
Recurrent calcifying aponeurotic fibroma of the hand: managing a rare hand tumour in an evolving healthcare landscape. 61
33431463 2021
47
Successful radiofrequency ablation of a huge left ventricular fibroma in a child. 61
33515543 2021
48
Endoscopic Resection of a Massive Ossifying Fibroma in the Sinonasal Cavity. 61
33534305 2021
49
Characterization of novel USP6 gene rearrangements in a subset of so-called cellular fibroma of tendon sheath. 61
32661296 2021
50
A Case of Large Calcifying Fibroma of Tendo-achilles Managed by En-block Resection and Tendon Reconstruction. 61
33187898 2021
Sources

Variations for Fibroma

About this section
Sources

Expression for Fibroma

About this section
Search GEO for disease gene expression data for Fibroma.
Sources

Pathways for Fibroma

About this section

Pathways related to Fibroma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.29 VIM SERPINA3 S100A9 S100A1 PECAM1 NF1
2
Striated Muscle Contraction 65 1
10.66 VIM DES ACTC1
Sources

GO Terms for Fibroma

About this section

Cellular components related to Fibroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.28 VIM SERPINA3 S100A9 PECAM1 MUC16 IVL
2 fascia adherens GO:0005916 8.96 DES CTNNB1

Biological processes related to Fibroma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.72 TSC1 PTCH1 NF1 CTNNB1 CDC73
2 cell-matrix adhesion GO:0007160 9.67 TSC1 CTNNB1 CD34
3 negative regulation of oxidative stress-induced neuron death GO:1903204 9.48 TSC1 CTNNB1
4 positive regulation of transcription elongation from RNA polymerase II promoter GO:0032968 9.46 CTNNB1 CDC73
5 regulation of cell-matrix adhesion GO:0001952 9.43 TSC1 NF1
6 smooth muscle tissue development GO:0048745 9.4 PTCH1 NF1
7 negative regulation of oligodendrocyte differentiation GO:0048715 9.37 NF1 CTNNB1
8 autocrine signaling GO:0035425 9.26 S100A9 CD68
9 endodermal cell fate commitment GO:0001711 9.16 CTNNB1 CDC73
10 muscle filament sliding GO:0030049 9.13 VIM DES ACTC1
11 glomerular endothelium development GO:0072011 8.62 PECAM1 CD34
Sources

Sources for Fibroma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....